Skip to main content

Advertisement

Table 1 Demographic and treatment-related characteristics of patients with vs. without adverse long-term quality of life (QoL) scores

From: Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study

  adverse long-term urinary QoL adverse long-term bowel QoL
  yes (n = 261) no (n = 35) yes (n = 264) no (n = 32)
patient age/years
median (range)
72 (51-83) 71 (45-84) 71 (51-82) 72 (45-84)
% fraction dose 1.8 Gy 69% 72% 72% 72%
% total dose 72 Gy 54% 56% 59% 55%
prostate volume/cc
median (range)
40 (18-107) 39 (11-151) 36 (14-107) 40 (11-151)
% NHT 34% 32% 38% 32%
PTV/cc
median (range)
338 (212-529) 330 (169-631) 339 (117-517) 330 (177-517)
bladder volume/cc
median (range)
220 (54-657) 192 (14-806) 181 (82-657) 194 (14-806)
rectum volume/cc
median (range)
102 (43-295) 97 (28-401) 93 (38-295) 98 (28-401)
AUC for bladder/%
median (range)
37 (12-69) 41 (7-98) 35 (7-78) 41 (7-98)
bladder volume within 90% isodose*/% 20 (5-46) 21 (2-64) 20 (3-54) 22 (2-57)
AUC for rectum/%
median (range)
52 (33-77) 51 (19-84) 47 (23-70) 52 (19-84)
rectum volume within 90% isodose*/% 27 (6-64) 28 (6-60) 24 (12-50) 28 (6-64)
  1. *100% = prescription dose of 70.2-72 Gy; 90% = 63.2-64.8 Gy